alexa Clostridium Difficile Flagellin FliC As An Adjuvant To Induce A Protective Gut Mucosal Immune Response
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Jean-Francois Bruxelle, Assaf Mizrahi, Anne Collignon and Claire Janoir
University of Paris-Su, France
Paris Saint Joseph Hospital Group, France
Posters & Accepted Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-058
The role of the bacterial flagellin immunogenicity has been reported. Thanks to its close interaction with the immune system, the flagellin represents an interesting adjuvant and vaccine candidate. Salmonella typhimurium flagellin (FLA-ST) has already been tested as an adjuvant to modulate the mucosal immunity. Here we assessed the interest of Clostridium difficile flagellin FliC as a mucosal adjuvant, first with ovalbumin (OVA) as antigen, secondly with the C. difficile S-layer protein (SlpA). Using OVA as an antigen, we compared the gut mucosal adjuvant capacity of FliC to FLA-ST and to cholera toxin (CT). After immunizations in a mouse model via the intra-rectal or intra-peritoneal route, the mucosal and systemic antibody responses against OVA (IgG and IgA) were analyzed by ELISA in intestinal contents and in sera of immunized mice. In addition, OVA-specific IgA and IgG producing cells were detected in the intestinal lamina propria by ELISPOT. We showed that FliC as an adjuvant in immunization via a mucosal and systemic route was able to stimulate both a gut mucosal and systemic antibody response against OVA. Then, in order to develop a mucosal vaccine to prevent C. difficile intestinal colonization, we assessed the role of FliC as an adjuvant when co-administrated with the C. difficile precursor of SlpA as an antigen. Rectal immunizations with SlpA precursor and FliC or CT as adjuvant were performed in a mouse model. After challenge, a significant decrease of C. difficile intestinal colonization was observed in immunized groups compared to the control group. Our results showed that the C. difficile FliC could be used as an adjuvant in mucosal vaccination strategy against C. difficile infections.

Jean-François Bruxelle is specialized in host-pathogen interactions acquiring multidisciplinary knowledge in immunology, microbiology and pharmacology. During his PhD, he mastered skills and learned new techniques through vaccine development with characterization of antigens, their vectorization and immunizations assays followed by the study of the immune response induced. His current project focuses on the development of a mucosal vaccine strategy targeting colonization factors of Clostridium difficile. The objective is to induce a local protection against C. difficile colonization; which is the first stage of the infection. This strategy could prevent the inflammatory response as well as the dissemination of bacteria in the environment.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version